OPK (OPKO Health Inc.) stock: $1.67, $1.25B market cap, $300.8M cash, $947.4M EV, $2.01B fully diluted market cap. Next expected readout: Oct-27. Lead program: CTAP101 (CKD Stage 3), Phase 2. Data from Fully Diluted's biotech stocks database.
Balance sheet
| Cash | $300.8M |
|---|
| Debt | $1.8M |
|---|
| Net cash | $299.0M |
|---|
| Enterprise value | $947.4M |
|---|
| Basic shares | 755.3M shares |
|---|
| Fully diluted shares | 1,204.6M shares |
|---|
| Fully diluted market cap | $2,011.7M |
|---|
| Cash per share | $0.40 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading OPK daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Nov 12 - Dec 24 | CTAP101 | Phase 2 | CKD Stage 3; CKD Stage 4; Secondary Hyperparathyroidism | — |
| Jan 12 - Feb 23 | OPK-88006 | Phase 2 | MASH | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
NGENLA
Approved · Active Modality: once-weekly human growth hormone injection
Aliases somatrogon-ghla, Somatrogon (hGH-CTP)
Target GH (growth hormone)
Partnerships Pfizer (exclusive worldwide development and commercialization license; commercialization led by Pfizer)
Indications- growth disturbance due to insufficient secretion of growth hormone in children and adolescents (approved in 50+ markets) (Stage not disclosed)
Status note Approved in more than 50 markets including US, EU, Japan, Canada, and Australia.
Rayaldee
Approved · Active Modality: extended-release oral calcifediol
Aliases extended release calcifediol
Partnerships Vifor Fresenius Medical Care Renal Pharma (development and commercialization agreement; worldwide except US, Canada, Latin America, Russia, China and other listed territories); Nicoya Macau (license agreement for development and commercialization in Greater China; amended April 30, 2026)
Indications- secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency (Stage not disclosed)
Status note FDA-approved; marketing authorizations in 11 European countries.
EBV vaccine
Phase 1 · Active Modality: nanoparticle vaccine
Target EBV gH/gL/gp42/gp350
Partnerships Merck (exclusive license and research collaboration; $50 million initial payment; up to $860 million in additional milestones; tiered royalties)
Indications- Epstein-Barr virus (Stage not disclosed)
Status note First participant dosed in the Phase 1 study in January 2025, triggering a $12.5 million milestone payment from Merck.
oral OXM
Stage not disclosed · Active Modality: oral peptide
Aliases dual GLP-1/glucagon peptide
Target GLP-1/glucagon
Partnerships Entera Bio (collaboration and license agreement; amended and restated February 2026)
Status note Oral dual agonist GLP-1/glucagon peptide program under the Entera collaboration; stage not stated in the current 10-Q.
LA-PTH
Preclinical · Active Modality: oral tablet (long-acting PTH analog)
Target PTH (parathyroid hormone)
Partnerships Entera Bio (amended and restated collaboration and license agreement, February 2026; 50/50 ownership and cost sharing)
Indications- hypoparathyroidism (Stage not disclosed)
Status note Daily long-acting PTH tablet under the Entera collaboration.
Per-asset detail extracted from the 10-Q filed 2026-07-27. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.